Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity

Pediatric Transplantation

Volumn 7, Issue 3, 2003, Pages 168-178

  Schwartz, Jennifer E ^a,b   Yeager, Andrew M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Graft vs. tumor; Graft vs. host disease; Hematopoietic stem cell; Non myeloablative; Preparative regimens; Reduced intensity; Transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; PENTOSTATIN; THYMOCYTE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; AGE DISTRIBUTION; CELLULAR IMMUNODEFICIENCY; CLINICAL RESEARCH; CYTOKINE PRODUCTION; EFFECTOR CELL; ENDOCRINE DISEASE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRANULOMATOSIS; GROWTH RETARDATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFERTILITY; KIDNEY CARCINOMA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; CHILD; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037980116     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00016.x     Document Type: Review

References (109)

1. THOMAS ED. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983: 1: 517-531.
2. JOHNSON BD, DROBYSKI WR, TRUITT RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993: 11: 329-336.
3. TRUITT RL, SHIH CY, LEFEVER AV, et al. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 1983: 131: 2050-2058.
4. VERDONCK LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999: 34: 129-136.
5. HOROWITZ MM, GALE RP, SONDEL PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555-562.
6. DROBYSKI WR, KEEVER CA, ROTH MS, et al. Salvage immuno-therapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993: 82: 2310-2318.
7. MACKINNON S, PAPADOPOULOS EB, CARABASI MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995: 86: 1261-1268.
8. KOLB HJ, SCHATTENBERG A, GOLDMAN JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995: 86: 2041-2050.
9. COLLINS RH, Jr., SHPILBERG O, DROBYSKI WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997: 15: 433-444.
10. JONES RJ, AMBINDER RF, PIANTADOSI S, SANTOS GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991: 77: 649653.
11. BEN-YOSEF R, OR R, NAGLER A, SLAVIN S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996: 348: 1242-1243.
12. LADENSTEIN R, LASSET C, HARTMANN O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994: 14: 37-46.
13. EIBL B, SCHWAIGHOFER H, NACHBAUR D, et al, Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996: 88: 1501-1508.
14. UENO NT, RONDON G, MIRZA NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998: 16: 986-993.
15. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756-763.
16. KHOURI IF, KEATING M, KORBLING M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998: 16: 2817-2824.
17. GREENBERG PD, CHEEVER MA, FEFER A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes. J Exp Med 1981: 154: 952-963.
18. JP OK, KOCIBAN DL, MACHEN LL, BUFFO MJ. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 1991: 8: 445-452.
19. AIZAWA S, SADO T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991: 52: 885-889.
20. TRUITT RL, ATASOYLU AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991: 8: 51-58.
21. SLAVIN S. Eradication of murine leukemia with histocompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol, Immunother 1981: 11: 155-158.
22. ANDERSON LD, Jr., SAVARY CA, MULLEN CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000: 95: 2426-2433.
23. GEORGES GE, STORB R, THOMPSON JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000: 95: 3262-3269.
24. ORSINI E, ALYEA EP, SCHLOSSMAN R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant 2000: 25: 623-632.
25. DOLSTRA H, FREDRIX H, VAN DER MEER A, et al. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor P58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant 2001: 27: 1087-1093.
26. CHARAK BS, BRYNES RK, GROSHEN S, CHEN SC, MAZUMDER A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990: 76: 2187-2190.
27. AGAH R, MALLOY B, KERNER M, et al. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice. Cancer Res 1989: 49: 5959-5963.
28. SYKES M, ROMICK ML, SACHS DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990: 87: 5633-5637.
29. HAMON MD, PRENTICE HG, GOTTLIEB DJ, et al. Immuno-therapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 1993: 11: 399-401.
30. BENYUNES MC, MASSUMOTO C, YORK A, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993: 12: 159-163.
31. RATANATHARATHORN V, UBERTI J, KARANES C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994: 84: 1050-1055.
32. BLAISE D, GASPARD MH, STOPPA AM, et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1990: 5: 7-12.
33. MARMONT AM, HOROWITZ MM, GALE RP, et al. T-Cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120-2130.
34. GOLDMAN JM, GALE RP, HOROWITZ MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988: 108: 806-814.
35. GALE RP, HOROWITZ MM, ASH RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994: 120: 646-652.
36. VAN BESIEN KW, DE LIMA M, GIRALT SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997: 19: 977-982.
37. DAZZI F, SZYDLO RM, CRADDOCK C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000: 95: 67-71.
38. PORTER DL, COLLINS RH, Jr., HARDY C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000: 95: 1214-1221.
39. WEIDEN PL, FLOURNOY N, THOMAS ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979: 300: 1068-1073.
40. WEIDEN PL, SULLIVAN KM, FLOURNOY N, STORB R, THOMAS ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529-1533.
41. SLAVIN S, NAPARSTEK E, NAGLER A, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995: 23: 1553-1562.
42. SALAMA M, NEVILL T, MARCELLUS D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000: 26: 1179-1184.
43. COLLINS RH, Jr., GOLDSTEIN S, GIRALT S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000: 26: 511-516.
44. McGUIRE WP. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors. Curr Probl Cancer 1998: 22: 135-177.
45. MATTHAY KK, SEEGER RC, REYNOLDS CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 1994: 12: 2382-2389.
46. NEGRIER S, MICHON J, FLORET D, et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 1991: 9: 1363-1370.
47. CHAN KW, ROGERS PC, FRYER CJ. Breast metastases after bone marrow transplantation for rhabdomyosarcoma. Bone Marrow Transplant 1991: 7: 171-172.
48. FROHLICH B, AHRENS S, BURDACH S, et al. High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. Klin Padiatr 1999: 211: 284-290.
49. MOSCARDO F, MARTINEZ JA, SANZ GF, et al. Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br J Haematol 2000: 111: 708-710.
50. BAY JO, CHOUFI B, POMEL C, et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 2000: 25: 681-682.
51. THOMAS ED, BLUME KG, FORMAN SJ, eds. Hematopoietic Cell Transplantation. Malden: Blackwell Science, 1999.
52. RINGDEN O, HOROWITZ MM, GALE RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993: 270: 57-60.
53. BORTIN MM, HOROWITZ MM, GALE RP, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992: 268: 607-612.
54. MICHALLET M, THOMAS X, VERNANT JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise De Greffe De Moelle (SFGM). Bone Marrow Transplant 2000: 26: 1157-1163.
55. BEARMAN SI, APPELBAUM FR, BUCKNER CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988: 6: 1562-1568.
56. GREEN S, WEISS GR. Southwest Oncology Group Standard Response Criteria, Endpoint Definitions and Toxicity Criteria. Invest New Drugs 1992: 10: 239-253.
57. HILL GR, TESHIMA T, GERBITZ A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999: 104: 459-467.
58. FERRARA JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000: 9: 299-306.
59. FERRARA JL, LEVY R, CHAO NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999: 5: 347-356.
60. FERRARA JL, ABHYANKAR S, GILLILAND DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 1993: 25: 1216-1217.
61. STORB R, YU C, WAGNER JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997: 89: 3048-3054.
62. GAMMIE JS, LI S, COLSON YL, et al. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. Exp Hematol 1998: 26: 927-935.
63. STORB R, YU C, BARNETT T, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999: 94: 1131-1136.
64. HUANG CA, FUCHIMOTO Y, SCHEIER-DOLBERG R, et al. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000: 105: 173-181.
65. SHARABI Y, ABRAHAM VS, SYKES M, SACHS DH. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992: 9: 191-197.
66. SINGHAL S, SAFDAR A, CHIANG KY, et al. Non-myeloablative allogeneic transplantation ('Microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplant 2000: 26: 1231-1233.
67. XUN CQ, McSWEENEY PA, BOECKH M, et al. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. Blood 1999: 94: 3273-3276.
68. GOMEZ-ALMAGUER D, RUIZ-ARGUELLES GJ, RUIZ-ARGUELLES A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant 2000: 25: 131-133.
69. GIRALT S, ESTEY E, ALBITAR M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997: 89: 4531-4536.
70. CARELLA AM, CHAMPLIN R, SLAVIN S, McSWEENEY P, STORB R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000: 25: 345-350.
71. SANDMAIER BM, McSWEENEY P, YU C, STORB R. Nonmyel-oablative transplants: preclinical and clinical results. Semin Oncol 2000: 27: 78-81.
72. McSWEENEY PA, NIEDERWIESER D, SHIZURU JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001: 97: 3390-3400.
73. VARADI G, OR R, KAPELUSHNIK J, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 1999: 34: 185-190.
74. SLAVIN S, NAGLER A, VARADI G, OR R. Graft vs auto immunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000: 28: 853-857.
75. ANDERLINI P, GIRALT S, ANDERSSON B, et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000: 26: 615-620.
76. NAGLER A, OR R, NAPARSTEK E, VARADI G, SLAVIN S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000: 28: 1096-1104.
77. MICHALLET M, BILGER K, GARBAN F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001: 19: 3340-3349.
78. NAGLER A, ACKERSTEIN A, KAPELUSHNIK J, et al. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999: 24: 339-342.
79. HORWITZ ME, BARRETT AJ, BROWN MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001: 344: 881-888.
80. AMROLIA P, GASPAR HB, HASSAN A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000: 96: 1239-1246.
81. WALTERS MC, PATIENCE M, LEISENRING W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001: 7: 665-673.
82. KRISHNAMURTI L, BLAZAR BR, WAGNER JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001: 344: 68.
83. STORB RF, CHAMPLIN R, RIDDELL SR, et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001: 375-391.
84. CHILDS R, CHERNOFF A, CONTENTIN N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000: 343: 750-758.
85. BREGNI M, DODERO A, PECCATORI J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002: 99: 4234-4236.
86. CHILDS RW, BRADSTOCK KF, GOTTLIEB D, KEFFORD R, BARRETT J. Non-myeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: results of a pilot study. Blood 2000: 96: 353b. (abstract no. 5277).
87. WASCH R, REISSER S, HAHN J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000: 26: 243-250.
88. ATKINS MB, LOTZE MT, DUTCHER JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999: 17: 2105-2016.
89. ROSENBERG SA, LOTZE MT, YANG JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993: 85: 622-632.
90. NEGRIER S, ESCUDIER B, LASSET C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais D'immunotherapie. N Engl J Med 1998: 338: 1272-1278.
91. OLEKSOWICZ L, DUTCHER JP. A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1999: 125: 101-108.
92. BORNHAUSER M, THIEDE C, SCHULER U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000: 26: 119-125.
93. WEISSINGER F, SANDMAIER BM, MALONEY DG, et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001: 98: 3584-3588.
94. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999: 94: 3234-3241.
95. SYKES M, PREFFER F, McAFEE S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999: 353: 1755-1759.
96. KHOURI IF, SALIBA RM, GIRALT SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001: 98: 3595-3599.
97. KOTTARIDIS PD, MILLIGAN DW, CHOPRA R, et al. In vivo campath-1h prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 2000: 96: 2419-2425.
98. GIRALT S, THALL PF, KHOURI I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001: 97: 631-637.
99. CHILDS RW, BAHCECI E, ENIAFE R, et al. Older patient age remains a risk factor for transplant related mortality (TRM) following nonmyeloablative allogeneic stem cell transplantation (NST). Blood 2000: 96: 520a. (abstract no. 2237).
100. CHILDS R, EPPERSON D, BAHCECI E, CLAVE E, BARRETT J. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 1999: 107: 396-400.
101. MALONEY DG, SAHEBI F, STOCKERL-GOLDSTEIN KE, et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 2001: 98: 434a. (abstract no. 1822).
102. YEAGER AM, SHINN C, PARDOLL DM. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 1991: 78: 3312-3316.
103. STEVENSON HC, FAUCI AS. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980: 39: 391-397.
104. ADKINS JC, PETERS DH, MARKHAM A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997: 53: 1005-1037.
105. VAN BESIEN K, DEMUYNCK H, LEMAISTRE CF, BOGAERTS MA, CHAMPLIN R. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant 1995: 15: 321-323.
106. SMYTH JF, PAINE RM, JACKMAN AL, et al. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 1980: 5: 93-101.
107. THOMAS ED. Total Body Irradiation Regimens for Marrow Grafting. Int J Radiat Oncol Biol Phys 1990: 19: 1285-8.
108. GABER AO, FIRST MR, TESI RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998: 66: 29-37.
109. OSTERBORG A, DYER MJ, BUNJES D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of Campath-IH Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997: 15: 1567-1574.